National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) is a component of the US National Institutes of Health dedicated to understanding, treating, and preventing infectious, immunologic, and allergic diseases. With an annual budget exceeding $6 billion, NIAID supports the largest network of publicly funded infectious disease clinical trials in the world, spanning HIV, tuberculosis, malaria, emerging viral pathogens, influenza, respiratory viruses, immune-mediated diseases, and now long COVID.
NIAID's clinical trial infrastructure includes the HIV/AIDS Clinical Trials Networks (ACTG, HVTN, IMPAACT, MTN), the Collaborative Antiviral Study Group (CASG), the Asthma and Allergic Diseases Cooperative Research Centers, the Precision Vaccines Program, and the COVID-19 Prevention Network (CoVPN). During the COVID-19 pandemic, NIAID-managed the ACTIV consortium — Accelerating COVID-19 Therapeutic Interventions and Vaccines — that rapidly initiated and coordinated master protocols across dozens of candidate therapeutics and vaccines including remdesivir, baricitinib, and molnupiravir.
Beyond infectious disease, NIAID funds trials in primary immune deficiency disorders, autoimmune conditions including type 1 diabetes, lupus, and IBD, and severe allergic conditions including food allergy (including landmark peanut allergy desensitization trials), eosinophilic esophagitis, and mastocytosis. NIAID-sponsored trials often incorporate biospecimen banking and deep immune phenotyping to advance mechanistic understanding alongside clinical endpoints.